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patients: a multicenter sub-group analysis of the
randomized-controlled open-label CGAO-REA
study
Raphaël Cinotti1, Carole Ichai2,3, Jean-Christophe Orban2,3, Pierre Kalfon4, Fanny Feuillet5,6, Antoine Roquilly7,8,
Bruno Riou9,10, Yvonnick Blanloeil1, Karim Asehnoune7,8 and Bertrand Rozec1,11*Abstract
Introduction: Hyperglycemia is a marker of poor prognosis in severe brain injuries. There is currently little data
regarding the effects of intensive insulin therapy (IIT) on neurological recovery.
Methods: A sub-group analysis of the randomized-controlled CGAO-REA study (NCT01002482) in surgical intensive
care units (ICU) of two university hospitals. Patients with severe brain injury, with an expected ICU length of
stay ≥48 hours were included. Patients were randomized between a conventional glucose management group
(blood glucose target between 5.5 and 9 mmol.L−1) and an IIT group (blood glucose target between 4.4 and
6 mmol.L−1). The primary outcome was the day-90 neurological outcome evaluated with the Glasgow outcome scale.
Results: A total of 188 patients were included in this analysis. In total 98 (52%) patients were randomized in the control
group and 90 (48%) in the IIT group. The mean Glasgow coma score at baseline was 7 (±4). Patients in the IIT group
received more insulin (130 (68 to 251) IU versus 74 (13 to 165) IU in the control group, P = 0.01), had a significantly
lower morning blood glucose level (5.9 (5.1 to 6.7) mmol.L−1 versus 6.5 (5.6 to 7.2) mmol.L−1, P <0.001) in the first
5 days after ICU admission. The IIT group experienced more episodes of hypoglycemia (P <0.0001). In the IIT group
24 (26.6%) patients had a favorable neurological outcome (good recovery or moderate disability) compared to 31
(31.6%) in the control group (P = 0.4). There were no differences in day-28 mortality. The occurrence of hypoglycemia
did not influence the outcome.
Conclusions: In this sub-group analysis of a large multicenter randomized trial, IIT did not appear to alter the day-90
neurological outcome or ICU morbidity in severe brain injured patients or ICU morbidity.Introduction
Numerous studies are available regarding blood glucose
(BG) control in the intensive care unit (ICU) setting [1,2]
and have led to the elaboration of international guidelines
[3,4]. On the other hand, randomized controlled trials* Correspondence: bertrand.rozec@chu-nantes.fr
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unless otherwise stated.focusing on severely brain-injured patients, such as those
with traumatic brain injury (TBI) or intra-cerebral he-
morrhage (ICH), are scarce. Clinical studies are mono-
centric [5], frequently retrospective [6] and performed in
small cohorts of patients [7]. Large randomized controlled
trials did not evaluate specifically the impact of tight
glucose control on neurological outcome in this specific
ICU population [2]. Moreover, all of these studies have
shown that this strategy increases the incidence of hypo-
glycemia that has been identified as an independent risk
factor of mortality in the general-ICU setting [8] and hasLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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pyruvate ratio in TBI patients [9]. Therefore, balancing
the potential beneficial effect of normalizing BG to the
higher risk of hypoglycemia is a real matter of debate in
brain-injured patients. Hyperglycemia has been clearly
identified as a marker of poor outcome in TBI [10], car-
diac arrest [11], ICH [12] and stroke [13]. If BG control
appears mandatory in the neuro-ICU setting to prevent
secondary brain damage and improve patient’s outcome
[14], the appropriate BG target remains unclear.
Not only normoglycemia, but insulin itself has been
reported to improve critically ill patients considering its
metabolic and anti-inflammatory effects [15,16]. Experi-
mental data suggest that insulin could increase astrocyte
glucose uptake [17] and could play a role in cerebral glu-
cose regulation in the cortex [18]. Finally, BG level after
brain injury is more dependent on cerebral glucose
utilization than BG level itself meaning that the appro-
priate glucose target to reach after brain insult remains
unknown [19]. We conducted a sub-group analysis of a
multicenter randomized-controlled open study (CGAO-
REA study-NCT01002482) [20] regarding the effects of
intensive insulin therapy (IIT) on neurological outcome
in severely brain-injured patients.
Material and methods
This study was a sub-group analysis of the non-blinded
parallel-group randomized controlled CGAO-REA study
(NCT01002482) [20] performed in two ICUs of French
university hospitals (Nantes and Nice). Written informed
consent was obtained before randomization, or delayed
consent was obtained from each patient whenever neuro-
logical recovery was deemed appropriate or from a legal
surrogate. The CGAO-REA study and ancillary studies
were approved by the Ethics Committee of the teaching
hospital of Tours, France.
Inclusion criteria
As described in the CGAO-REA study, adults who re-
quired at least three days of ICU stay were eligible for this
study. Patients in a moribund state at admission were not
eligible.
All patients with a severe brain injury, with an expected
ICU length of stay of at least three days at admission who
were included in the CGAO-REA study, were eligible for
this sub-group analysis; brain injuries included: TBI,
aneurysmal subarachnoid hemorrhage (SAH), stroke,
ICH without aneurysm, resuscitated cardiac arrest,
brain tumor, cerebral abscess or central nervous system
infection.
Brain injury management
Brain-injured patients with a Glasgow coma score (GCS)
≤8 were intubated and were mechanically ventilated[21]. Patients were sedated with either midazolam (0.2
to 0.5 mg.kg−1.h−1) or propofol (1 to 5 mg.kg−1.h−1) and
continuous infusion of fentanyl (2 to 5 μg.kg−1.h−1) or
sufentanil (0.2 to 0.5 μg.kg−1.h−1). Management of pa-
tients was consistent with the guidelines of the Brain
Trauma Foundation [22]. Subsequently, intra-cerebral
pressure (ICP) monitoring was performed in patients
with GCS ≤8 and with an abnormal brain computed
tomography (CT) scan or whenever deemed appropriate
by the attending intensivist, using either an intrapar-
enchymental device or a ventriculostomy in the presence
of hydrocephalus [23]. Cerebral perfusion pressure
(CPP) was maintained in the range of 60 to 70 mmHg
[21,22] with continuous infusion of norepinephrine when
needed [21,22]. Since there is little evidence in the setting
of neuro-vascular diseases regarding CPP thresholds,
the same thresholds were applied in patients with ICP
monitoring other than TBI, with respect to specific
management, such as blood pressure targets following
SAH or ICH [23]. To prevent secondary brain insults,
the following standards of care were also applied: nor-
moxia (PaO2 ≥ 80 mmHg), normocapnia (35 ≤ PCO2 ≤
45 mmHg), body temperature between 36°C and 38°C
and maintenance of a serum osmolality ranging between
280 and 320 mOsm.kg−1 [24].
Intracranial hypertensive episodes defined by an
ICP ≥20 mmHg [22], were treated by boli of sedatives
and a bolus of mannitol (0.5 g.kg−1) [25]. Mannitol
was used in the setting of plasma osmolality ≤320 mosm.
kg−1. In the case of refractory intracranial hypertension
(ICP ≥20 mmHg for more than 15 minutes despite usual
first-line treatment) [22], barbiturates (sodium thiopental)
were added with an intravenous bolus of 2 to 3 mg.kg−1
followed by a continuous infusion of 2 to 3 mg.kg−1.h−1
[26]. Twenty-four hour therapeutic mild-hypothermia
was a standard of care regarding resuscitated cardiac ar-
rest [27] and was discussed in the setting of refractory ICP
hypertension [28].
Sedation was stopped whenever the control of ICP
was deemed appropriate.
Blood glucose management
In the CGAO study, randomization was stratified ac-
cording to the type of admission (scheduled surgical,
emergency surgical, medical), diabetic status prior ad-
mission and conventional glucose control management
in the ICU before the beginning of the study. BG man-
agement is described elsewhere [20]. Briefly, patients
were included in the standard of care group (Control
group) or the IIT group. In the IIT group, tight comput-
erized BG control was performed with the assistance of
the CGAO (Contrôle glycémique assisté par Ordinateur)
software (LK2®, Saint-Avertin, France) set for targeting
a BG range between 4.4 and 6 mmol.L−1. The CGAO
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system for BG control management that produces, at
bedside, explicit recommendations regarding not only
insulin titration (with an algorithm based on a propor-
tional integral controller [29]), but also time for the next
BG measurement and dose of intravenous glucose for
correction of a possible hypoglycemia. The attending
nurse could accept or decline the CGAO recommen-
dations after each BG measurement, in the case of high
doses of insulin administration which could lead to
hypoglycemia. Nurses could ask the attending physician
for assistance. In the control arm, BG management was
based on current practice already used in the participating
ICU before the beginning of the study and the targeted
BG range was between 6 and 9 mmol.L−1 in Nantes and
between 5.5 and 9 mmol.L−1 in Nice. All patients under-
went an enteral nutrition protocol which included early
initiation of enteral nutrition (day 1 after ICU admission),
enteral intake target of 20 to 30 kCal.kg−1.day−1 [30] and
the absence of residual gastric volume monitoring.
Data collection
Patient characteristics and neurologic data at baseline
were analyzed as well as BG level and mean doses of
insulin within the first five days which was considered as
the acute phase of brain-injury and intra-cerebral hy-
pertension. Episodes of moderate (<3.3 mmol.L−1) and
severe (<2.2 mmol.L−1) hypoglycemia were recorded.
Outcome measures
The primary outcome was the neurologic outcome at
day 90 following ICU admission and was assessed using
the Glasgow outcome scale (GOS) via phone call blinded
to treatment group [24]. Patients were dichotomized into
good neurologic outcome defined by a good recovery and
moderate disability (GOS 1 to 2) and poor neurologic out-
come regarded as severe disability, vegetative state and
death (GOS 3, 4, 5). Secondary outcomes were: neuro-
surgical events during ICU stay, in-ICU death, neurologic
outcome at day 28 following ICU admission, 28-day-ICU-
free days and 28-day-ventilator-free days.
Statistical analysis
Continuous data are expressed as mean ± standard devi-
ation for parametric data and as median (25th to 75th per-
centiles) for non-parametric data. Categorical data are
expressed as number (%). A univariate analysis was per-
formed regarding the primary and secondary outcomes
between the control and the intervention groups. Para-
metric and non-parametric values were compared using
the unpaired Student t-test and Mann-Whitney tests,
respectively. Categorical values were compared with the
chi2 test. We also performed a multivariate analysis re-
garding the risk factors of day 90 good neurologicaloutcome [24]. Factors identified as potential prognosis fac-
tors for day 90 good neurological outcome by the univari-
ate analysis with a cut-off P value at 0.2 were included in
the logistic regression model and backward selection was
applied. The calibration of the model was tested by a
Hosmer-Lemeshow’s test. The final model was presented
with a crude odds ratio (OR) and 95% confidence interval
(CI). All P values were two-tailed and P values less than
0.05 were considered significant. Statistical analysis was
performed with SAS statistical software (SAS 9.3 Institute,
Cary, NC, USA).Results
A total of 496 patients from the ICUs of Nantes and
Nice were included in the CGAO-REA study, and 188 of
them (37%) were included in our sub-group analysis fo-
cused on brain-injured patients. Ninety four patients
were included per center. Ninety (48%) patients were
included in the IIT group and 98 (52%) in the control
group. One hundred and seventy eight (95%) patients
underwent mechanical ventilation for at least two days.
The two groups were comparable except for GCS and
body mass index (BMI), which were lower in the IIT
group. In addition, more patients received ICP monitor-
ing in the intervention group (n = 47, 52.2%) than in the
control group (n = 34, 34.6%) (P = 0.01). Patient charac-
teristics are provided in Table 1.
Each morning laboratory BG was significantly lower in
the IIT group (5.9 (5.1 to 6.7) mmol.L−1) than in the
control group (6.5 (5.6 to 7.2) mmol.L−1) during the first
five days of ICU hospitalization (P <0.001). In the IIT
group, patients received significantly higher doses of in-
sulin (130 (68 to 251) IU versus 74 (13 to 165) IU in the
control group (P = 0.01)), within the first five days of
ICU hospitalization. There were significantly more episodes
of moderate hypoglycemia in the IIT group (n = 46, 51.1%)
than in the control group (n = 19, 19.3%) (P <0.001).
Six (6.67%) patients experienced an episode of severe
hypoglycemia in the IIT group and four (4%) in the
control group (P = 0.5). In-ICU glycemic events are sum-
marized in Table 2.Outcomes
In the IIT group, 24 (26.6%) patients had a favorable
neurological outcome (good recovery, moderate disability)
compared to 32 (31.6%) in the control group (P = 0.40)
(Figure 1). There were no significant differences regarding
the day-28 neurological outcome, in-ICU death, the num-
ber of ventilation-free days and the number of ICU-free
days (Table 3). There were no significant differences
regarding in-ICU neuro-surgical events (Table 4). The
occurrence of hypoglycemia did not significantly modify
the day-90 neurological outcome (P = 0.70).
Table 1 Characteristics of severe-brain injured patients
Control group IIT group P value
Number = 98 Number = 90
Age 53 (15) 53 (16) 0.90
SAPS II 45 (15) 47 (17) 0.50
GCS on admission 7 (4) 6 (3) 0.02
Sex male/female 60(61)/38(39) 51(56)/39(44) 0.50
BMI 26 (5) 24 (4) 0.02
Diabetes mellitus 9 (9.2) 4 (4.4) 0.20
Laboratory glycemia
on admission (mmol.l−1)
8.1 (6.8 to 9.8) 8.3 (6.8 to 9.6) 0.50
Monitoring of ICP 34 (35) 47 (52) 0.01*
Cause of brain injury,
number(%)
0.50
Traumatic brain injury 19 (19) 22 (24)
Aneurysmal subarachnoid
hemorrhage
28 (29) 32 (36)
Intra-cerebral hemorrhage 12 (12) 10 (11)
Malignant stroke 11 (11) 5 (6)
Resuscitated cardiac arrest 13 (13) 13 (14)
Other 15 (15) 8 (9)
Characteristics of patients included in the CGAO-REA study and suffering from
a severe brain injury, in two neuro-intensive care units of two university hospitals.
Continuous parametric data are expressed as mean (standard deviation) and
non-parametric data as median (25th to 75th percentile) and categorical data as
number (%). Continuous data were analyzed with Student’s t test. Categorical
data were analyzed with χ2 test. BMI: body mass index (kg.m−2); GCS: Glasgow
Coma Score; ICP: intracerebral pressure; IIT: intensive insulin therapy; SAPS II:
Simplified Acute Physiology Score II.
Figure 1 Day 90 neurological outcome following ICU admission.
The figure represents the day-90 neurological outcome after ICU
admission in severely brain-injured patients in the control group (blood
glucose range between 5.5 and 9 mmol.L−1) and the intensive insulin
therapy (IIT) group (blood glucose range between 4.4 and 6 mmol.L−1).
Good neurological outcome is classified as a Glasgow outcome scale
(GOS) score of 1 to 2 (good recovery, moderate disability). Poor
neurological outcome is classified as a GOS score of 3, 4 or 5 (severe
disability, vegetative state, death). χ2 test.
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On univariate analysis, the prognosis factors of favorable
neurological outcome were: other cause of brain injury
than brain trauma, the absence of decompressive cra-
niectomy, the absence of nosocomial pneumonia during
ICU hospitalization, lower blood glucose level at ICU
admission, administration during ICU of anti-epilepticTable 2 In-ICU blood glucose events
Control group IIT group P value
Number = 98 Number = 90
Median of the first five
days morning laboratory
blood glucose (mmol.l−1)
6.5 (5.6 to 7.2) 5.9 (5.1 to 6.7) < 0.001a
Episodes of moderate
hypoglycemia
19 (19.3) 46 (51.1) < 0.001b
Episodes of severe
hypoglycemia
4 (4) 6 (6.6) 0.50
Patients treated with insulin 81 (82.6) 87 (96.6) 0.002b
Total of insulin dose (IU)
in the first five days
74 (13 to 165) 130 (68 to 251 0.01a
aStudent’s t test; bχ2 test. Moderate hypoglycemia was define as a blood
glucose level <3.3 mmol.L−1. Severe hypoglycemia was defined as <2.2 mmol.L−1.
Continuous data are expressed as median (25th to 75th percentile) and
categorical data as N (%). IIT: intensive insulin therapy.drugs, a higher administration of insulin dose in the first
five days after ICU admission and a higher number of
ventilation-free days. In the multivariate analysis, all
causes of brain injury except trauma, administration
of anti-epileptic drugs and a higher number of ventilation-
free days were independent and significant prognosis fac-
tors of favorable outcome (Table 5).
Discussion
Our study shows that tight computerized BG control had
no significant effect on neurological recovery at day-90
following ICU admission in the sub-group of brain-injured
patients extracted from the multi-center randomized-
controlled CGAO-REA trial. The incidence of moderate
hypoglycemia was higher in the IIT group but this did
not significantly modify neurological outcome.
Acute neurological injuries bear significant mortality
and are one of the major causes of severe disabilityTable 3 Outcome of severely brain-injured patients
Control group IIT group P value
Number = 98 Number = 90
Ventilation-free days 8.5 (0 to 22) 9 (0 to 20) 0.40
ICU-free days 8.5 (0 to 20) 8 (0 to 20) 0.50
Day-28 mortality 28 (28.6) 26 (28.9) 0.90
Day-28 good
neurologic outcome
31 (31.6) 24 (26.6) 0.40
Crude outcome of severely brain-injured patients included in a sub-group
analysis of the CGAO-REA study. Ventilation and ICU-free days are expressed
between ICU admission and Day-28. Good neurologic outcome was defined as
a good recovery or moderate disability (Glasgow outcome scale score 1 to 2)
[24]. Poor neurologic outcome was defined as severe disability or vegetative
state or death (Glasgow outcome scale score 3, 4, 5) [24]. Continuous data are
expressed as median (25th to 75th percentile) and categorical data as number
(%). Continuous data were analyzed with Student’s t test. Categorical data
were analyzed with χ2 test. IIT: intensive insulin therapy.
Table 4 Neuro-surgical events in the ICU in severely brain-injured patients
Control group IIT group P value
Number = 98 Number = 90
Patients presenting at least one episode of ICP ≥25 mmHg
during ICP monitoring
17 (17.3) 23 (25.5) 0.20
Administration of mannitol during ICU 19 (19.4) 28 (31.1) 0.06*
Barbiturates use during ICU 9 (9.2) 14 (15.6) 0.20
Specific neuro-surgical events in the ICU in a sub-group analysis of severely brain-injured patients in two university hospitals of the CGAO-REA study. Categorical
data are expressed as number (%) and analyzed with χ2 test. ICP: intra-cerebral pressure; IIT: intensive insulin therapy.
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and incur substantial health-care costs [23,31]. Hyper-
glycemia is a well-recognized secondary brain insult and
is a marker of poor outcome in every brain-injured pa-
tient, leading to increased brain damage [10]. BG control
is, therefore, mandatory and has proved efficacious in
improving neurological outcome in stroke [14]. How-
ever, such results have not been clearly evaluated in ICU
patients with neurologic diseases and high ICP. Few
studies have been performed in the neuro-ICU setting.
In a single center randomized study IIT did not result in
any neurologic improvement in a critically ill neurologic
population [32]. In a large series of 178 SAH patients,
the authors pointed out that an elevated BG level
(>7.8 mmol.L−1) was associated with a poorer outcome,
but most patients displayed a mild to moderate form of
SAH [33]. Also, the authors used a conventional BG
control. In a large retrospective analysis of a single-center
cohort of various neurologic injuries, Graffignano et al.
[6] reported that IIT was associated with more episodes of
hypoglycemia, an increased in-hospital length of stay and
a higher mortality. In this study, the severity of neurologic
injury and the occurrence of intracranial hypertension
were unknown [6]. It is, therefore, difficult to draw con-
clusions from such studies about the appropriate BG level
to target in the neuro-ICU setting.Table 5 Exploratory multivariate analysis of risk factors
of day-90 favorable neurological outcome
Adjusted OR CI95%(OR) P value
Cause of brain injury 0.004
Traumatic brain injury 1
Neuro-vascular cause
(SAH, ICH, malignant stroke)
1.27 (0.46 to 3.54)
Resuscitated cardiac arrest 3.99 (1.02 to 15.61)
Other etiologies (brain tumor,
central nervous system
infection, cerebral vascularitis)
7.92 (2.10 to 29.91)
Anti-epileptic drugs 2.99 (1.10 to 8.16) 0.03
Number of ventilation-free days 1.11 (1.07 to 1.16) <0.001
Risk factors of day-90 favorable neurological outcome defined as good recovery
and moderate disability. Hosmer and Lemeshow goodness-of-fit test P = 0.94.
CI95%: 95% confidence interval; ICH: intracerebral hemorrhage; OR: odds ratio;
SAH: subarachnoid hemorrhage.Yang et al. [5] performed a randomized controlled
study in severe traumatic brain-injured patients. Inter-
estingly, the IIT group with a 4.4 to 6.1 mmol.L−1 target
exhibited a lower infections rate, lower ICU length of
stay and a better six-month neurologic outcome evalu-
ated with the GOS. The main drawback in this study is
that the control group received insulin only when patients
had a BG level >11.1 mmol.L−1, which is not a standard of
care [2], and no data were available regarding the manage-
ment of insulin. In experimental rat models of TBI, the
provision of glucose has been reported to improve cere-
bral metabolism and decrease neuronal injury [34], and
insulin resulted in an increased astrocyte glucose uptake
[17], suggesting that a large intake of glucose combined
with a high insulin infusion after acute neurological injury
could prevent secondary brain damages. To the best of
our knowledge, we provide the first results obtained in a
multi-center study regarding BG management in severely
brain-injured patients and we failed to demonstrate any
significant difference in the neurological outcome between
patients treated with IIT or conventional BG control.
It is noteworthy that a slight lowering in BG levels in
our intervention group was associated with a higher inci-
dence of moderate hypoglycemia. Several studies suggest
that hypoglycemia is an independent mortality factor in
the ICU [2], which was not observed in the CGAO-REA
study [20]. Data regarding hypoglycemia and neurologic
diseases are conflicting. In a study including 14 conse-
cutive TBI patients undergoing IIT, Vespa et al. [35] dem-
onstrated an increased cerebral glutamate and lactate/
pyruvate ratio and low cerebral glucose assessed with local
microdialysis. There was, however, no relationship be-
tween serum glucose rates and global rates of glycolysis,
evaluated with positron emission tomography suggesting
the possible lack of connection between serum and cere-
bral glucose. In this study, it is also unknown whether
these cerebral stress markers have long-term clinical con-
sequences [35]. Moreover, recent data suggest a neuropro-
tective role of lactate during hypoglycemia, as the brain
shifts lactate utilization over glucose, when both substrates
are available [36]. In an experimental model, Suh et al.
[37] have recently demonstrated that BG reperfusion is
responsible for neuronal cell death after hypoglycemia
which was not responsible per se for neuronal apoptosis.
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ing BG control, several relevant hypoglycemia severity
markers [38], such as duration of hypoglycemic episodes
and hypoglycemic-related neurological signs, are not avail-
able, mostly because of sedation or previous neurological
impairment. Put together, all these issues make it difficult
to ascertain the potential neurological consequences of
hypoglycemia in severely brain-injured patients.
Risk factors associated with favorable neurological out-
come were resuscitated cardiac arrest or miscellaneous
causes of brain injury compared to TBI, the administra-
tion of anti-epileptic drugs during ICU stay and the
number of ventilation-free days (Table 5). Studies in re-
suscitated cardiac arrest usually focus on in-hospital
mortality and neurological status at hospital discharge
[39], which makes it difficult to compare to TBI. This re-
sult must be cautiously interpreted and remains purely
exploratory. Administration of anti-epileptic drugs in the
early course of TBI [40] or SAH [23] is mandatory to
prevent secondary seizure following brain injury. However,
there is little evidence on whether early seizure prophy-
laxis improves long-term outcome.
There is growing evidence that respiratory complica-
tions frequently occur in brain-injured patients [41] and
could impact the outcome [42]. It is therefore interesting
that a higher number of ventilation-free days was inde-
pendently associated with a better outcome in our study.
An evidence-based bundle is able to reduce the duration
of mechanical ventilation in severely brain-injured-patients
[43] but there is not yet enough data to assess the impact
of such a strategy on the long-term neurological outcome.
Our study has several limitations. This is a sub-group
analysis of a large multi-center study and our results
remain purely exploratory. In the initial study [20], there
was no stratification on the type or severity of neurologic
injury. It is, therefore, possible to retrieve an imbalance of
patient’s severity. Nonetheless, hyperglycemia is a source
of secondary brain damage and a marker of poor progno-
sis in all types of brain injury and one can expect that IIT
could have a potential effect on neurological recovery.
Finally, IIT could serve a beneficial role in neurologic re-
covery; this effect could remain undetected since patients
in the IIT group had a greater neurologic severity at base-
line (lower GCS in this group). In our centers, barbiturates
and osmotherapy were commonly used in the most severe
patients. To the best of our knowledge, IIT is not advo-
cated to induce ICP hypertension. We believe that the use
of barbiturates and osmotherapy probably reflect the
severity of brain injury.
Despite significant differences, BG levels were very
close in both groups without any real clinical relevance,
blunting a possible clinical impact of close BG control
on neurological recovery in severely brain-injured patients.
In the same way, the absence of hypoglycemia-relatedneurological worse outcome must be cautiously interpre-
ted because most of the hypoglycemic episodes were
moderate. Lastly, the severity of hypoglycemia was only
defined by its biological threshold without considering
either the duration of these episodes or the usual clinical
signs of hypoglycemia.
Conclusions
Tight BG control did not result in an improved neu-
rological outcome in severely brain-injured patients but
significantly increased the rate of moderate episodes of
hypoglycemia. Since the most appropriate BG threshold
in this specific ICU-population remains unknown, a mo-
derate BG management goal between 5.5 and 9 mmol.L−1
seems preferable.
Key messages
 Intensive insulin therapy does not affect outcome
in severely brain-injured patients.
 Intensive insulin therapy does not affect ICU
morbidity in severely brain-injured patients.
 Hypoglycemia is not a marker of poor neurological
outcome in severely brain-injured patients.
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